

REMARKS/ARGUMENT

Claim 11 has been amended to correct its dependency (note the antecedent to TGR183).
No new matter is added

The Office Action requires restriction between what are asserted to be four (4) separate and distinct inventions:

Group I – Claims 1-4 to an assay involving the TGR4 polypeptide;

Group II – Claims 5 to 7 and 14-16 to a method *inter alia* of treatment using a compound that modulates a TGR4 polypeptide;

Group III – Claims 8-11 to an assay involving the TGR183 polypeptide; and


Group IV – Claims 12, 13 and 17-19 to a method *inter alia* of treatment using a compound that modulates a TGR4 polypeptide.

In response to the Restriction Requirement, applicants elect the invention of Group III, claims 8-11.

Applicants request reconsideration of the pending claims.

Respectfully submitted,

Dated: August 16, 2005

By. 
Joseph M. Skerpon
Registration No. 29,864

BANNER & WITCOFF, LTD.
1001 G Street, N.W. - Eleventh Floor
Washington, D.C. 20001-4597
(202) 824-3000

JMS/bao
915602-1